Aptinyx has received three grants worth potentially $2.85 million from the National Institutes of Health to research and develop new therapeutic compounds for neuropathic pain and age-related cognitive decline.
The NIH’s National Institute of Neurological Disorders and Stroke awarded Aptinyx a one-year, $1.25 million grant to fund the development of compounds for neuropathic pain treatment, the biopharmaceutical company said Thursday.
NINDS could award an additional $1.09 million to fund year two which depends on the availability of NIH funds and project progress, Aptinyx added.
The National Institute on Aging funds preclinical research on the impact of Aptinyx N-methyl-D-aspartate receptor modulators on memory loss and cognitive function in aging brain, Aptinyx noted.
Aptinyx will study the effects of NMDA receptor modulators on neuropathic pain related to chemotherapy-induced peripheral neuropathy under a grant from the National Cancer Institute.
The company currently tests its NYX-2925 small-molecule modulator on volunteers for neuropathic pain associated with diabetic peripheral neuropathy.
The Food and Drug Administration granted fast-track designation to Aptinyx’s development program.